CDRI and Zydus will jointly undertake preclinical research

Based on research conducted at Central Drug Research Institute (CDRI), Lucknow and data from antibody-based therapies (biologics), a protein Sclerostin, has emerged as a promising drug target for treating Chronic kidney disease (CKD) induced osteoporosis as well as postmenopausal osteoporosis.

A collaborative research agreement was signed by Zydus Lifesciences, Ahmedabad and Central Drug Research Institute, Lucknow. Under this agreement, CDRI and Zydus will jointly undertake preclinical research. Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets.

Dr Radha Rangarajan, Director, CSIR-CDRI said, “CSIR-CDRI has worked extensively in the area of bone metabolism under the leadership of Dr Naibedya Chattopadhyay.”

Pankaj Patel, Chairman, Zydus Lifesciences, on the occasion said, “CSIR-CDRI's deep-rooted expertise in biomedical research, coupled with Zydus's innovative approach to drug discovery and development, creates a powerful synergy.” Together, the two organisations will explore new avenues for treating bone metabolism disorders, ensuring that CKD patients have access to effective and affordable therapies that improve their quality of life, reiterated the chairman.